home / stock / uncy / uncy news

UNCY News and Press, Unicycive Therapeutics Inc. From 12/22/22

Stock Information
Company Name: Unicycive Therapeutics Inc.
Stock Symbol: UNCY
Market: NASDAQ
Website: unicycive.com
Menu
UNCY UNCY Quote UNCY Short UNCY News UNCY Articles UNCY Message Board
Get UNCY Alerts

News, Short Squeeze, Breakout and More Instantly...
UNCY - Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom

LOS ALTOS, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, announced today that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Ki...
UNCY - Unicycive Therapeutics, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

ORLANDO, FL / ACCESSWIRE / December 9, 2022 / RedChip Companies will air a new interview with Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with unmet medical needs, on The RedChip Money Report® on Bloomberg TV, this Sat...

UNCY - Planned Government Move To Expand Access To Drugs For End-Stage Renal Disease Patients Could Shine The Spotlight On Unicycive

(NewsDirect) In the U.S., reimbursement of dialysis expenses by the Centers for Medicare & Medicaid Services (CMS) is done using a prospective payment system (PPS) which enables the payout of a predetermined amount to providers of dialysis services. In October, the CMS published its ...

UNCY - Unicycive to Participate in Upcoming Investor Conferences

LOS ALTOS, Calif., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with unmet medical needs, today announced senior management will participate in two upcoming conferences: S...
UNCY - Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy

Treatment with UNI-494 improved contrast vision in animal models of geographic atrophy (GA) GA is an advanced form of Age-related Macular Degeneration (AMD) and there are currently no FDA-approved drugs to slow the progression of AMD LOS ALTOS, Calif., Nov. 21, 2022 ...

UNCY - Unicycive Therapeutics GAAP EPS of -$0.37 misses by $0.09, revenue of $0.95M

Unicycive Therapeutics press release ( NASDAQ: UNCY ): Q3 GAAP EPS of -$0.37 misses by $0.09 . Revenue of $0.95M. For further details see: Unicycive Therapeutics GAAP EPS of -$0.37 misses by $0.09, revenue of $0.95M

UNCY - Unicycive Announces Third Quarter Financial Results and Provides Business Update

Topline results by year-end as enrollment completed for pivotal bioequivalence study of RENAZORB™ (lanthanum dioxycarbonate), an investigational phosphate binder for the treatment of hyperphosphatemia in Chronic Kidney Disease (CKD) patients on dialysis On track to file N...
UNCY - Unicycive Completes Enrollment of Pivotal Bioequivalence Study for RENAZORB(TM) (lanthanum dioxycarbonate), an Investigational Treatment for Hyperphosphatemia in Chronic Kidney Disease (CKD) Patients on Dialysis

Topline Data Expected by Year End 2022 On Track to File the NDA in 2023 LOS ALTOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today ...

UNCY - Unicycive's Doug Jermasek, EVP-Corporate Development Discusses the Importance of Medication Compliance and the Issues with Pill Burden

--News Direct-- Contact Details Anne Marie Fields - Stern Investor Relations +1 212-362-1200 annemarie.fields@sternir.com Company Website https://unicycive.com/ View original content to download multimedia: https://newsdirect.com/news/unicyc...

UNCY - Unicycive’s Doug Jermasek, EVP-Corporate Development Discusses the Importance of Medication Compliance and the Issues with Pill Burden

(NewsDirect) Contact Details Anne Marie Fields - Stern Investor Relations +1 212-362-1200 annemarie.fields@sternir.com Company Website https://unicycive.com/ Copyright (c) 2022 TheNewswire - All rights reserved.

Previous 10 Next 10